These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 8957578)

  • 1. Anti-Salmonella activity of CP-99,219, a novel azabicyclo-naphthridone fluoroquinolone.
    Qadri SM; Cunha BA; Ueno Y; Walters EA
    Chemotherapy; 1996; 42(6):439-42. PubMed ID: 8957578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of sparfloxacin against Salmonella typhi.
    Qadri SM; Ueno Y; Almodovar E
    Chemotherapy; 1997; 43(1):6-9. PubMed ID: 8996735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of Salmonella typhi and Brucella melitensis to the new fluoroquinolone rufloxacin (MF 934).
    Qadri SM; Ayub A; Ueno Y; Saldin H
    Chemotherapy; 1993; 39(5):311-4. PubMed ID: 8396527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activity of enoxacin and other fluoroquinolones against multi-resistant strains of Salmonella typhi.
    Hannan A
    Curr Med Res Opin; 1992; 12(9):560-3. PubMed ID: 1316257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revised ciprofloxacin breakpoints for Salmonella Typhi: its implications in India.
    Balaji V; Sharma A; Ranjan P; Kapil A
    Indian J Med Microbiol; 2014; 32(2):161-3. PubMed ID: 24713903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergism of ciprofloxacin and trimethoprim against Salmonella enterica serovar typhi isolates showing reduced susceptibility to ciprofloxacin.
    Mandal S; Mandal MD; Pal NK
    Chemotherapy; 2004 Jun; 50(3):152-4. PubMed ID: 15272228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The susceptibility of Salmonella sp. to various antibiotics].
    Willke A; Altay G; Erdem B
    Mikrobiyol Bul; 1988 Jan; 22(1):17-24. PubMed ID: 3273593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae.
    Crump JA; Barrett TJ; Nelson JT; Angulo FJ
    Clin Infect Dis; 2003 Jul; 37(1):75-81. PubMed ID: 12830411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens.
    O'Hare MD; Felmingham D; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(4):253-7. PubMed ID: 2941257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparative activity of pefloxacin, enoxacin, ciprofloxacin and 13 other antimicrobial agents against enteropathogenic microorganisms.
    Vanhoof R; Hubrechts JM; Roebben E; Nyssen HJ; Nulens E; Leger J; De Schepper N
    Infection; 1986; 14(6):294-8. PubMed ID: 3546145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of azithromycin compared with other macrolides and oral antibiotics against Salmonella typhi.
    Metchock B
    J Antimicrob Chemother; 1990 Jan; 25 Suppl A():29-31. PubMed ID: 2154435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series.
    Slinger R; Desjardins M; McCarthy AE; Ramotar K; Jessamine P; Guibord C; Toye B
    BMC Infect Dis; 2004 Sep; 4():36. PubMed ID: 15380025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype typhi, United Kingdom.
    Threlfall EJ; Ward LR
    Emerg Infect Dis; 2001; 7(3):448-50. PubMed ID: 11384525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in antibiotic susceptibility of enteric fever isolates in East London.
    Dave J; Sefton A; de Pinna E; Woodford N; Meade R; Jordan M; Grant K; Holliman R; Millar M
    Travel Med Infect Dis; 2015; 13(3):230-4. PubMed ID: 25964222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validity of nalidixic acid screening in fluoroquinolone-resistant typhoid salmonellae.
    Butt T; Khan MY; Ahmad RN; Salman M; Afzal RK
    J Coll Physicians Surg Pak; 2006 Jan; 16(1):31-4. PubMed ID: 16441985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of Brucella melitensis to the new fluoroquinolone PD 131628: comparison with other drugs.
    Qadri SM; Ueno Y
    Chemotherapy; 1993; 39(2):128-31. PubMed ID: 8384544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolone resistance in Salmonella typhi and S. paratyphi A in Bangalore, India.
    Joshi S; Amarnath SK
    Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):308-10. PubMed ID: 16950486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi.
    Booker BM; Smith PF; Forrest A; Bullock J; Kelchlin P; Bhavnani SM; Jones RN; Ambrose PG
    Antimicrob Agents Chemother; 2005 May; 49(5):1775-81. PubMed ID: 15855495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.